Diffusion Pharmaceuticals Inc (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) a clinical stage biotech firm focused on the advancement of unique small molecule therapeutics targeting cancer and other hypoxia-related diseases, stated that the report from its Phase 1/2 clinical study assessing the efficacy and safety of trans sodium crocetinate in glioblastoma multiforme has been published in the peer-reviewed “Journal of Neurological Sciences” (JNS).
Report from the Phase 1/2 clinical study in 59 patients demonstrated that 36.3% of the TSC dose patients lived two years, as against the historical two-year survival rates in a range of 27% to 30%. TSC, Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) lead product candidate, is developed to target the tumor’s lowered oxygen microenvironment. The drug re-oxygenates cancerous tissue, hence making the cancer cells more prone to existing radiation therapy and chemotherapy.
David Kalergis, the Chairman and CEO, reported that the publication of the report in the JNS offers peer-reviewed validation and increases the visibility of Diffusion across major stakeholder audiences. The very promising report from Phase 1/2 clinical study supports their plan to advance into Phase III clinical advancement.
The article outlines the report of a Phase 1/2 study intended to evaluate the therapeutic impact of adding TSC to radiation treatment in 59 diagnosed GBM subjects. In this study, all subjects received radiation with the medicine temozolomide beginning either after biopsy or surgery of the tumor.
TSC was given around 45 minutes prior to each radiation session 3 days per week over the 6 weeks of radiation treatment. Considerable tumor shrinkage was noted in many subjects, with tumors in 11 subjects disappearing completely.
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) reported that JNS is the peer-reviewed periodical of the American Association of Neurological Surgeons. Its data was previously issued in the web edition of JNS last year and was originally reported in July 2015.
Oxygen deprivation at the cellular level is the product of rapid tumor growth, prompting the tumor to expand its blood supply. Cancerous tumor cells flourish with hypoxia and the resultant variations in the tumor microenvironment lead in “treatment-resistance” to chemotherapy and radiation therapy.
Using a unique, proprietary mechanism of action, Diffusion Pharmaceuticals Inc (NASDAQ:DFFN)’s lead drug TSC neutralizes tumor hypoxia , and hence treatment-resistance by carefully re-oxygenating tumor tissue.
In the last trading session, the stock price of Diffusion Pharmaceuticals jumped over 28% to close at $3.16. The 52-week high of the stock is $26 while the 52-week low point is noted at $2.53. After the recent gain, the market cap stands at around $32 million.
|Last Price a/o 3:21 PM EST||$3.16|
|Market Cap (mlns)||$32.71M|
|Shares Outstanding (mlns)||10.35M|
|Share Float (mlns)||6.85M|
|Short Interest Ratio||0.07|
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.